Novel technologies are being sought to replace the traditional pesticides used to protect plants, particularly edible plants such as cereals. A new collaborative project between the University of Helsinki and the French National Centre for Scientific Research (CNRS) is shedding light on the efficacy of environmentally friendly RNA-based vaccines that protect plants from diseases and pests.
Plant diseases and pests cause considerable crop losses and threaten global food security. The diseases and pests have traditionally been fought with chemical pesticides, which spread throughout our environment and may be hazardous to human health, beneficial organisms and the environment.
“A new approach to plant protection involves vaccinating plants against pathogens with double-stranded RNA molecules that can be sprayed directly on the leaves,” explains Dr Minna Poranen of the Molecular and Integrative Biosciences Research Programme at the University of Helsinki’s Faculty of Biological and Environmental Sciences.
The vaccine triggers a mechanism known as RNA interference, which is an innate defence mechanism of plants, animals and other eukaryotic organisms against pathogens. The vaccine can be targeted to the chosen pathogen by using RNA molecules which share sequence identity with the pest’s genes and prevents their expression.
This means that the double-stranded RNA molecules do not affect the expression of genes in the protected plant, but only target the plant disease or pest. RNA is also a common molecule in nature that degrades rapidly rather than building up in the environment.
“The challenge in developing RNA-based vaccines to protect plants has involved the production of RNA molecules. Double-stranded RNA molecules have been produced through chemical synthesis, both as drug molecules and for research purposes, but such production methods are inefficient and expensive for plant protection,” Poranen states.
As part of the Academy of Finland’s Synthetic Biology Research Programme, Poranen’s group has developed a new production method for double-stranded RNA molecules. Together with researchers at the CNRS, the group has demonstrated the efficacy of RNA-based vaccines produced using the new method against plant virus infections. The method utilises the RNA amplification system of a bacteriophage, i.e. a bacteria-destroying virus, and the RNA production takes place in bacterial cells. This new method will enable the effective production of RNA-based vaccines and promote the development and adoption of RNA-based plant protection methods.
“It’s difficult to predict when the vaccine will be made available because no relevant legislation exists yet,” Poranen says.
The Latest on: RNA plant vaccines
via Google News
The Latest on: RNA plant vaccines
- Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronaviruon March 21, 2020 at 4:12 am
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to ... agility derived from the platform nature of mRNA vaccine design ...
- What It’s Like to Be Part of the First Coronavirus Vaccine Trialon March 20, 2020 at 8:08 am
On January 13, less than a week after COVID-19 was identified as the virus behind the outbreak in Wuhan, researchers at Cambridge-based biotech company Moderna proposed a vaccine to fight it. A little ...
- First patients dosed with potential coronavirus vaccineon March 17, 2020 at 4:35 am
The vaccine relies on custom-built messenger RNA to produce an immune response ... It took Moderna a mere 42 days to produce a few hundred vials of the experimental vaccine at the high-flying ...
- Trial of Coronavirus Vaccine Made by Moderna Begins in Seattleon March 16, 2020 at 6:11 pm
The first testing in humans of an experimental vaccine for the new coronavirus began on Monday, the National Institute of Allergy and Infectious Diseases announced. The main goal of this first set of ...
- We’ve Got The Vaccine, Says Pentagon-Funded Companyon March 13, 2020 at 7:22 am
“But they’re different technologies. Some are RNA- or DNA-based vaccines that have not yet been proven in any indication yet, let alone this one. Hopefully, they’ll be successful.” How did Clark’s ...
- Canadian company produces viable vaccine candidate for COVID-19on March 12, 2020 at 7:45 pm
“But they’re different technologies. Some are RNA- or DNA-based vaccines that have not yet been proven in any indication yet, let alone this one. Hopefully, they’ll be successful.” Medicago is a ...
- Coronavirus vaccine: Canadian company claims to have found a cure and could do human tests in weekson March 12, 2020 at 7:11 pm
“But they’re different technologies. Some are RNA or DNA-based vaccines that have not yet been proven in any indication yet, let alone this one. Hopefully, they’ll be successful.” Mr Clark said his ...
- Beth Israel is working with Johnson & Johnson on a coronavirus vaccineon March 12, 2020 at 1:52 pm
If the answer is yes, Janssen has a plant in Leiden, Netherlands, prepared to manufacture 300 million doses ... Moderna, the Cambridge-based biotech, last month delivered an RNA-based vaccine it ...
- RNA vaccines are coronavirus frontrunnerson March 11, 2020 at 7:27 am
RNA vaccines consist of messenger RNA strands. They are injected into the body, usually within lipid nanoparticles. These merge with cells. Once inside, the RNA sequence is translated by ribosomes to ...
via Bing News